Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24766688)

1.

Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal.

Cheng JC, Bazan JG, Wu JK, Koong AC, Chang DT.

Pract Radiat Oncol. 2014 May-Jun;4(3):198-206. doi: 10.1016/j.prro.2013.07.011. Epub 2013 Aug 29.

PMID:
24766688
2.

Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.

Bazan JG, Luxton G, Mok EC, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):700-6. doi: 10.1016/j.ijrobp.2011.12.072. Epub 2012 Mar 11.

PMID:
22414279
3.

Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.

Bazan JG, Luxton G, Kozak MM, Anderson EM, Hancock SL, Kapp DS, Kidd EA, Koong AC, Chang DT.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):983-91. doi: 10.1016/j.ijrobp.2013.09.017. Epub 2013 Oct 22.

PMID:
24161422
4.

Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Mell LK, Schomas DA, Salama JK, Devisetty K, Aydogan B, Miller RC, Jani AB, Kindler HL, Mundt AJ, Roeske JC, Chmura SJ.

Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1431-7. Epub 2007 Nov 8.

PMID:
17996390
5.
6.
7.

Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.

Rose BS, Aydogan B, Liang Y, Yeginer M, Hasselle MD, Dandekar V, Bafana R, Yashar CM, Mundt AJ, Roeske JC, Mell LK.

Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):800-7. doi: 10.1016/j.ijrobp.2009.11.010. Epub 2010 Apr 17.

8.

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1356-65. Epub 2006 Jun 6.

PMID:
16757127
9.

Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.

Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61.

PMID:
16168830
10.

Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.

Chapet O, Kong FM, Lee JS, Hayman JA, Ten Haken RK.

Radiother Oncol. 2005 Nov;77(2):176-81. Epub 2005 Oct 26.

PMID:
16256230
11.

Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.

Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):153-8. doi: 10.1016/j.ijrobp.2010.09.030. Epub 2010 Nov 20.

PMID:
21095071
12.

Normal tissue complication probability estimation by the Lyman-Kutcher-Burman method does not accurately predict spinal cord tolerance to stereotactic radiosurgery.

Daly ME, Luxton G, Choi CY, Gibbs IC, Chang SD, Adler JR, Soltys SG.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2025-32. doi: 10.1016/j.ijrobp.2011.03.004. Epub 2011 Apr 29.

PMID:
21531516
13.

Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.

Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J.

Radiother Oncol. 2005 May;75(2):157-64.

PMID:
15890421
14.

Analysis of radiation-induced liver disease using the Lyman NTCP model.

Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK.

Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21. Erratum in: Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1422.

PMID:
12095546
15.

Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.

Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, Reiter E.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87.

PMID:
15380569
16.

Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study.

Erpolat OP, Alco G, Caglar HB, Igdem S, Saran A, Dagoglu N, Aslay I, Ozsaran Z, Demirci S, Keven E, Guney Y, Akmansu M, Kilic D, Bayman E, Etiz D, Mandel NM.

Eur J Gynaecol Oncol. 2014;35(1):62-6.

PMID:
24654465
17.
18.

Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.

Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B.

Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1504-10. doi: 10.1016/j.ijrobp.2008.04.046.

PMID:
18640499
19.

Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

Maguire PD, Sibley GS, Zhou SM, Jamieson TA, Light KL, Antoine PA, Herndon JE 2nd, Anscher MS, Marks LB.

Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):97-103.

PMID:
10477012
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk